Inclusion Criteria:

- Confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease

- Adequate organ and bone marrow function as assessed by laboratory tests

- Evaluable disease or disease measurable per Response Evaluation Criteria in Solid
Tumors (RECIST)

- Agreement to use an effective form of contraception for the duration of the study

Exclusion Criteria:

- History of Grade >/= 3 fasting hyperglycemia

- History of diabetes requiring regular medication

- History of malabsorption syndrome or other condition that would interfere with
enteral absorption

- Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or
thrombolytic agents

- Prior anti-cancer therapy (e.g., chemotherapy, biologic therapy, or hormonal therapy)
within a specified timeframe of the first dose of study treatment

- Uncontrolled current illness

- Active autoimmune disease requiring the equivalent of >10 mg/day of prednisone

- Clinically significant history of liver disease, including cirrhosis, current alcohol
abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C
virus

- Known HIV infection

- New York Heart Association (NYHA) Class II or greater congestive heart failure

- Active ventricular arrhythmia requiring medication

- Pregnancy, lactation, or breastfeeding

- Known significant hypersensitivity to study drugs or excipients

- History of arterial thromboembolic disease within 6 months of first study treatment

- No more than two prior chemotherapy regimens for metastatic disease

- No prior taxane therapy for metastatic disease